Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILTZAC vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries and decreased myocardial contractility and conduction velocity.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Chronic stable angina,Atrial fibrillation or flutter,Paroxysmal supraventricular tachycardia,Off-label: Prevention of migraine, Raynaud's phenomenon
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral: 30-120 mg 3-4 times daily; maximum 480 mg/day. IV: 0.25 mg/kg over 2 min, then 0.35 mg/kg after 15 min if needed; continuous infusion 5-15 mg/hour.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life: 3.5-5.0 hours (healthy adults). Prolonged in elderly (6-8 hours) and in hepatic impairment (10-12 hours).
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal: 60-70% as metabolites, 2-4% unchanged; Biliary/Fecal: 20-30% as metabolites.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
80-85% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
5-6 L/kg (suggests extensive tissue distribution).
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral immediate-release: 40-60% (due to extensive first-pass hepatic metabolism). Extended-release: 30-40%. Intravenous: 100%.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min, reduce dose by 25%. For GFR <10 m L/min, reduce dose by 50%.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Oral: 1-3 mg/kg/day divided 3-4 times; maximum 3 mg/kg/day. IV: 0.25 mg/kg over 2 min; may repeat 0.35 mg/kg after 15 min; infusion 5-15 mcg/kg/min.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at lowest dose (30 mg 3-4 times daily) due to increased bioavailability and reduced clearance; titrate slowly. IV dose: 0.2 mg/kg over 2 min.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None.
None
May cause heart block, bradycardia, exacerbation of heart failure, hypotension, and hepatotoxicity. Monitor liver function, ECG, and blood pressure. Avoid abrupt discontinuation; taper gradually.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (except with pacemaker), second- or third-degree AV block (except with pacemaker), hypotension (systolic <90 mm Hg), cardiogenic shock, acute myocardial infarction with pulmonary congestion, hypersensitivity to diltiazem, concomitant use of ivabradine, and concurrent use with strong CYP3A4 inhibitors when diltiazem is given intravenously.
None
Avoid grapefruit and grapefruit juice; they may increase diltiazem levels and risk of side effects. Alcohol may enhance blood pressure-lowering effects and cause dizziness. A high-fat meal may increase absorption, but this is not clinically significant.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
First trimester: No definitive evidence of teratogenicity in animal studies; human data limited. Second and third trimesters: Chronic use may cause fetal bradycardia, hypoxia, and growth restriction due to maternal hypotension and reduced placental perfusion.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted in breast milk with low levels. Milk-to-plasma ratio is approximately 0.28. Caution advised; monitor infant for bradycardia and hypotension.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No standard dose adjustment required; however, increased plasma volume may reduce drug levels. Titrate to therapeutic effect with careful blood pressure monitoring.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Diltzac is a calcium channel blocker (diltiazem) used for hypertension, angina, and atrial fibrillation. Avoid in patients with sick sinus syndrome (without pacemaker), second/third-degree AV block, or severe hypotension. Use with caution in hepatic impairment and renal failure. Monitor heart rate and ECG for bradycardia. Adjust dose with CYP3A4 inhibitors (e.g., grapefruit) or inducers. Advise gradual withdrawal to avoid rebound hypertension.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take exactly as prescribed; do not stop abruptly or change dose without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking Diltzac.,Do not drive or operate heavy machinery if you experience dizziness or lightheadedness.,Monitor for signs of heart failure (swelling of ankles, feet, or sudden weight gain) and report immediately.,Your doctor may need to do regular blood tests to check liver function and monitor your heart rate and blood pressure.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILTZAC vs AMVAZ, answered by our medical review team.
DILTZAC is a Calcium Channel Blocker that works by Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries and decreased myocardial contractility and conduction velocity.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILTZAC and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILTZAC is: Oral: 30-120 mg 3-4 times daily; maximum 480 mg/day. IV: 0.25 mg/kg over 2 min, then 0.35 mg/kg after 15 min if needed; continuous infusion 5-15 mg/hour.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILTZAC and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILTZAC is classified as Category C. First trimester: No definitive evidence of teratogenicity in animal studies; human data limited. Second and third trimesters: Chronic use may cause fetal bradycardia, hypoxia, and . AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.